RITA can induce cell death in p53-defective cells independently of p53 function via activation of JNK/ SAPK and p38

Cell Death and Disease

Volumn 5, Issue 7, 2014, Pages

  Weilbacher, A ^a   Gutekunst, M ^a   Oren, M ^b   Aulitzky, W E ^c   Van Der Kuip, H ^a  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^c ROBERT BOSCH HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BCL 2; PROTEIN P53; REACTIVATION OF P53 AND INDUCTION OF TUMOR CELL APOPTOSIS; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; THIOPHENE DERIVATIVE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CASPASE; FURAN DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE P38; NSC 652287;

APOPTOSIS; ARTICLE; CANCER CELL LINE; CELL CYCLE; CELL DEATH; CONTROLLED STUDY; ENZYME ACTIVATION; FIBROBLAST; GENE INDUCTION; HUMAN; HUMAN CELL; LYMPHOCYTE; MITOCHONDRIAL MEMBRANE; PRIORITY JOURNAL; PROTEIN EXPRESSION; DEFICIENCY; DRUG EFFECTS; GENETICS; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASES; CELL LINE, TUMOR; FURANS; HUMANS; MAP KINASE KINASE 4; P38 MITOGEN-ACTIVATED PROTEIN KINASES; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84905487588     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.284     Document Type: Article

References (55)

1. Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer 2009; 9: 749-758.
2. Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 2008; 9: 402-412.
3. Godefroy N, Bouleau S, Gruel G, Renaud F, Rincheval V, Mignotte B et al. Transcriptional repression by p53 promotes a Bcl-2-insensitive and mitochondria-independent pathway of apoptosis. Nucleic Acids Res 2004; 32: 4480-4490.
4. Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P et al. p53 has a direct apoptogenic role at the mitochondria. Mol Cell 2003; 11: 577-590.
5. Leu JI-J, Dumont P, Hafey M, Murphy ME, George DL. Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat Cell Biol 2004; 6: 443-450.
6. Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 2004; 303: 1010-1014.
7. Aylon Y, Oren M. p53: guardian of ploidy. Mol Oncol 2011; 5: 315-323.
8. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell 2009; 137: 413-431.
9. Oren M, Rotter V. Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol 2010; 2: a001107.
10. Goldstein I, Marcel V, Olivier M, Oren M, Rotter V, Hainaut P et al. Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies. Cancer Gene Ther 2011; 18: 2-11.
11. Rivlin N, Brosh R, Oren M, Rotter V. Mutations in the p53 tumor suppressor gene. Genes Cancer 2011; 2: 466-474.
12. Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 2009; 9: 701-713.
13. Wade M, Li Y-C, Wahl GM. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer 2013; 13: 83-96.
14. Stegh AH. Targeting the p53 signaling pathway in cancer therapy-the promises, challenges and perils. Expert Opin Ther Targets 2012; 16: 67-83.
15. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP. Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer 2009; 9: 862-873.
16. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303: 844-848.
17. Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, Hilton H et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci USA 2006; 103: 1888-1893.
18. Shangary S, Ding K, Qiu S, Nikolovska-Coleska Z, Bauer JA, Liu M et al. Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer. Mol Cancer Ther 2008; 7: 1533-1542.
19. Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LG, Masucci M et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 2004; 10: 1321-1328.
20. Enge M, Bao W, Hedström E, Jackson SP, Moumen A, Selivanova G et al. MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53. Cancer Cell 2009; 15: 171-183.
21. Zhao CY, Grinkevich VV, Nikulenkov F, Bao W, Selivanova G. Rescue of the apoptoticinducing function of mutant p53 by small molecule RITA. Cell Cycle Georget Tex 2010; 9: 1847-1855.
22. Gutekunst M, Oren M, Weilbacher A, Dengler MA, Markwardt C, Thomale J et al. p53 hypersensitivity is the predominant mechanism of the unique responsiveness of testicular germ cell tumor (TGCT) cells to cisplatin. PLoS One 2011; 6: e19198.
23. Saha MN, Jiang H, Mukai A, Chang H. RITA inhibits multiple myeloma cell growth through induction of p53-mediated caspase-dependent apoptosis and synergistically enhances nutlin-induced cytotoxic responses. Mol Cancer Ther 2010; 9: 3041-3051.
24. Wei C-L, Wu Q, Vega VB, Chiu KP, Ng P, Zhang T et al. A global map of p53 transcription factor binding sites in the human genome. Cell 2006; 124: 207-219.
25. Zhao CY, Szekely L, Bao W, Selivanova G. Rescue of p53 function by small-molecule RITA in cervical carcinoma by blocking E6-mediated degradation. Cancer Res 2010; 70: 3372-3381.
26. Burmakin M, Shi Y, Hedström E, Kogner P, Selivanova G. Dual targeting of wild type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro. Clin Cancer Res 2013; 19: 5092-5103.
27. Grinkevich VV, Nikulenkov F, Shi Y, Enge M, Bao W, Maljukova A et al. Ablation of key oncogenic pathways by RITA-reactivated p53 is required for efficient apoptosis. Cancer Cell 2009; 15: 441-453.
28. Dö tsch V, Bernassola F, Coutandin D, Candi E, Melino G. p63 and p73, the ancestors of p53. Cold Spring Harb Perspect Biol 2010; 2: a004887.
29. Collavin L, Lunardi A, Del Sal G. p53-family proteins and their regulators: hubs and spokes in tumor suppression. Cell Death Differ 2010; 17: 901-911.
30. Li Y, Prives C. Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function? Oncogene 2007; 26: 2220-2225.
31. Saha MN, Jiang H, Yang Y, Zhu X, Wang X, Schimmer AD et al. Targeting p53 via JNK pathway: a novel role of RITA for apoptotic signaling in multiple myeloma. PLoS One 2012; 7: e30215.
32. Rinaldo C, Prodosmo A, Siepi F, Moncada A, Sacchi A, Selivanova G et al. HIPK2 regulation by MDM2 determines tumor cell response to the p53-reactivating drugs nutlin-3 and RITA. Cancer Res 2009; 69: 6241-6248.
33. Hedström E, Eriksson S, Zawacka-Pankau J, Arné r ESJ, Selivanova G. p53-dependent inhibition of TrxR1 contributes to the tumor-specific induction of apoptosis by RITA. Cell Cycle Georget Tex 2009; 8: 3576-3583.
34. Spinnler C, Hedström E, Li H, de Lange J, Nikulenkov F, Teunisse AF et al. Abrogation of Wip1 expression by RITA-activated p53 potentiates apoptosis induction via activation of ATM and inhibition of HdmX. Cell Death Differ 2011; 18: 1736-1745.
35. Yang J, Ahmed A, Poon E, Perusinghe N, de Haven Brandon A, Box G et al. Small-Molecule activation of p53 blocks hypoxia-inducible factor 1a and vascular endothelial growth factor expression in vivo and leads to tumor cell apoptosis in normoxia and hypoxia. Mol Cell Biol 2009; 29: 2243-2253.
36. Yang J, Ahmed A, Ashcroft M. Activation of a unique p53-dependent DNA damage response. Cell Cycle Georget Tex 2009; 8: 1630-1632.
37. Ahmed A, Yang J, Maya-Mendoza A, Jackson DA, Ashcroft M. Pharmacological activation of a novel p53-dependent S-phase checkpoint involving CHK-1. Cell Death Dis 2011; 2: e160.
38. Shen H-M, Liu Z. JNK signaling pathway is a key modulator in cell death mediated by reactive oxygen and nitrogen species. Free Radic Biol Med 2006; 40: 928-939.
39. Adler V, Schaffer A, Kim J, Dolan L, Ronai Z. UV irradiation and heat shock mediate JNK activation via alternate pathways. J Biol Chem 1995; 270: 26071-26077.
40. Hara T, Namba H, Yang TT, Nagayama Y, Fukata S, Kuma K et al. Ionizing radiation activates c-Jun NH2-terminal kinase (JNK/SAPK) via a PKC-dependent pathway in human thyroid cells. Biochem Biophys Res Commun 1998; 244: 41-44.
41. Sánchez-Perez I, Murguía JR, Perona R. Cisplatin induces a persistent activation of JNK that is related to cell death. Oncogene 1998; 16: 533-540.
42. Lee H, Park MT, Choi BH, Oh ET, Song MJ, Lee J et al. Endoplasmic reticulum stress-induced JNK activation is a critical event leading to mitochondria-mediated cell death caused by b-lapachone treatment. PLoS One 2011; 6: e21533.
43. Shi Y, Nikulenkov F, Zawacka-Pankau J, Li H, Gabdoulline R, Xu J et al. ROS-dependent activation of JNK converts p53 into an efficient inhibitor of oncogenes leading to robust apoptosis. Cell Death Differ 2014; 21: 612-623.
44. Shaulian E. AP-1-the Jun proteins: oncogenes or tumor suppressors in disguise? Cell Signal 2010; 22: 894-899.
45. Dhanasekaran DN, Reddy EP. JNK signaling in apoptosis. Oncogene 2008; 27: 6245-6251.
46. Lei K, Davis RJ. JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis. Proc Natl Acad Sci USA 2003; 100: 2432-2437.
47. Srivastava RK, Mi QS, Hardwick JM, Longo DL. Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis. Proc Natl Acad Sci USA 1999; 96: 3775-3780.
48. Yamamoto K, Ichijo H, Korsmeyer SJ. BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol Cell Biol 1999; 19: 8469-8478.
49. Tromp JM, Geest CR, Breij EC, Elias JA, van Laar J, Luijks DM et al. Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia. Clin Cancer Res Off J Am Assoc Cancer Res 2012; 18: 487-498.
50. Rivera MI, Stinson SF, Vistica DT, Jorden JL, Kenney S, Sausville EA et al. Selective toxicity of the tricyclic thiophene NSC 652287 in renal carcinoma cell lines: differential accumulation and metabolism. Biochem Pharmacol 1999; 57: 1283-1295.
51. Fanta S, Sonnenberg M, Skorta I, Duyster J, Miething C, Aulitzky WE et al. Pharmacological inhibition of c-Abl compromises genetic stability and DNA repair in Bcr-Abl-negative cells. Oncogene 2008; 27: 4380-4384.
52. Schmid JO, Dong M, Haubeiss S, Friedel G, Bode S, Grabner A et al. Cancer cells cue the p53 response of cancer-associated fibroblasts to cisplatin. Cancer Res 2012; 72: 5824-5832.
53. Skorta I, Oren M, Markwardt C, Gutekunst M, Aulitzky WE, van der Kuip H et al. Imatinib mesylate induces cisplatin hypersensitivity in Bcr-Abl+ cells by differential modulation of p53 transcriptional and proapoptotic activity. Cancer Res 2009; 69: 9337-9345.
54. Elmore SP, Nishimura Y, Qian T, Herman B, Lemasters JJ. Discrimination of depolarized from polarized mitochondria by confocal fluorescence resonance energy transfer. Arch Biochem Biophys 2004; 422: 145-152.
55. Haubeiss S, Schmid JO, Mü rdter TE, Sonnenberg M, Friedel G, van der Kuip H et al. Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts. Mol Cancer 2010; 9: 168.